Clinical trials
Phase 4 Macular Edema trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 6 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 8 |
| 2012 | 3 |
| 2013 | 8 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 44 |
| Unknown status | 7 |
| Terminated | 6 |
| Withdrawn | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 6 |
| Allergan | 3 |
| Asociación para Evitar la Ceguera en México | 3 |
| Medical University of Vienna | 3 |
| Northern California Retina Vitreous Associates | 2 |
| Unity Health Toronto | 2 |
| University of Campinas, Brazil | 2 |
| Università degli Studi di Brescia | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Bayer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Macular Edema | 60 |
| Retinal Vein Occlusion | 17 |
| Diabetic Retinopathy | 7 |
| Cataract | 5 |
| Diabetes Mellitus | 5 |
| Uveitis | 4 |
| Vision Disorders | 4 |
| Macular Degeneration | 3 |
| Choroidal Neovascularization | 2 |
| Eye Pain | 2 |
Trials
Showing 1 to 25 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.